Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 4/20 | 0.43 |
| ▸ | MMP8 | P22894 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP12 | P39900 | 3/20 | 0.43 |
| ▸ | MMP14 | P50281 | 3/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008655 | 0.88 | ITGB3 (0.41) | MMP9MMP8MMP2MMP12MMP14 | |
| SCHEMBL20008649 | 0.87 | MMP9 (0.46) | MMP9MMP8MMP2MMP12MMP14 | |
| SCHEMBL20008646 | 0.76 | ITGB3 (0.43) | MMP9MMP8MMP2MMP12MMP14 | |
| SCHEMBL20012060 | 0.76 | ITGB3 (0.38) | MMP9MMP8MMP2MMP12MMP14 | |
| SCHEMBL18720249 | 0.76 | CASP3 (0.40) | MMP9MMP8MMP2MMP12MMP14 | |
| SCHEMBL13165330 | 0.75 | NOD1 (0.44) | FOLH1 | |
| SCHEMBL12664921 | 0.75 | NOD1 (0.44) | FOLH1 | |
| SCHEMBL12664935 | 0.75 | NOD1 (0.44) | FOLH1 | |
| SCHEMBL20008694 | 0.74 | ITGB3 (0.59) | FOLH1ITGB3ITGA2B | |
| SCHEMBL7415627 | 0.74 | ITGB3 (0.49) | MMP2CA1CA2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | MMP9 521/4885MMP8 731/4885MMP2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.